Abstracts tagged "cytokines"

Abstract Number: 146 • 2013 ACR/ARHP Annual Meeting
The Arthritis Severity Locus Cia4 Is An Early Regulator of IL-6, IL-1β, and NFκB activators’ Expression in Pristane-Induced Arthritis
Max Brenner^1,2, Teresina Laragione^1,2 and Percio Gulko^1,2, ¹Center for Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ²Molecular Medicine, Hosftra North Shore-LIJ School of Medicine, Manhasset, NY
Background/Purpose: Cia4 is a quantitative trait locus on rat chromosome 7 that regulates disease severity and joint damage in three models of rheumatoid arthritis including…
Abstract Number: 1859 • 2013 ACR/ARHP Annual Meeting
OX40⁺ T Cells and OX40L⁺ B Cells Accumulate In The Inflamed Joints and OX40 Signalling Is Skewed Towards Autoreactivity
Julie Kristine Laustsen¹, Tue Rasmussen², Malene Hvid³ and Bent Deleuran⁴, ¹Department of Medical Biomedicine, Aarhus University, Aarhus N, Denmark, ²Dept of Biomedicine, Aarhus University, Aarhus, Denmark, ³Dept. of Clinical Medicine, Aarhus University, Aarhus, Denmark, ⁴Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by the presence of autoantibodies and autoreactive T cells, leading to synovitis and joint destruction. The…
Abstract Number: 958 • 2013 ACR/ARHP Annual Meeting
Serum Cytokine Changes In Rituximab-Treated Rheumatoid Arthritis Patients
Tamarah D. de Jong¹, Saskia Vosslamber¹, Wilco de Jager², Hennie G. Raterman³, Alexandre E. Voskuyl⁴, Kyra A. Gelderman¹ and Cornelis L. Verweij⁵, ¹Pathology, VU University Medical Center, Amsterdam, Netherlands, ²Pediatric Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁴Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁵Pathology and Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Although rituximab therapy is successful in the majority of rheumatoid arthritis (RA) patients, 30-40% of patients do not respond. The mechanism behind this is…
Abstract Number: 1844 • 2013 ACR/ARHP Annual Meeting
Rheumatoid Arthritis, Sjogren’s Syndrome and Systemic Lupus Erythematosus Patients Have a Distinct Spectrum Of Serum Anticytokine Autoantibodies
Sarthak Gupta^1,2, Ioanna P. Tatouli³, Lindsey B. Rosen², Sarfaraz A. Hasni¹, Richard M. Siegel¹, Steven M. Holland², Haralampos M. Moutsopopoulos³ and Sarah K. Browne², ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ³School of Medicine, National University of Athens, Athens, Greece
Background/Purpose: Anticytokine autoantibodies are pathogenic in many hematologic, pulmonary and infectious diseases. However, the prevalence and significance of anticytokine autoantibodies in rheumatic conditions is poorly…
Abstract Number: 929 • 2013 ACR/ARHP Annual Meeting
Blockade Of TNFα Produced By TSLP-Primed CD1c Myeloid Dendritic Cells Skews T Cell Response To Th2 Activity In Rheumatoid Arthritis Patients
F.M. Moret¹, T.R.D.J. Radstake², J.W.J. Bijlsma¹, F.P.J.G. Lafeber¹ and J.A.G. van Roon³, ¹Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Thymic stromal lymphopoietin (TSLP) is well known for its potent activation of myeloid dendritic cells (mDCs) to induce Th2-mediated immune responses. Additionally, TSLP and…
Abstract Number: 2858 • 2013 ACR/ARHP Annual Meeting
Inhibition Of Chronic Pain By IL4-10 Synerkine Is Superior To IL-4 Or IL-10 Monotherapy: A Novel Strategy To Restrain Pain In Rheumatic Diseases
Niels Eijkelkamp¹, Sarita Hartgring², Cristine Steen-Louws³, Hanneke Willemen⁴, Qiu-Ling Mao-Ying⁵, Cobi Heijnen⁵, Erik Hack⁶, Annemiek Kavelaars⁵ and J.A.G. van Roon⁷, ¹Laboratory of Neuroimmunology and Developmental Origins of Disease (NIDOD), UMC Utrecht, Utrecht, Netherlands, ²Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³UMC Utrecht, Utrecht, Netherlands, ⁴NIDOD, UMC Utrecht, Utrecht, Netherlands, ⁵MD Anderson Cancer Center, Houston, TX, ⁶Immunology, UMC Utrecht, Utrecht, Netherlands, ⁷Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Chronic pain is a major problem in many diseases, including RA and OA, arising from inflammation or structural damage. It is often associated with glial…
Abstract Number: 1845 • 2013 ACR/ARHP Annual Meeting
Soluble Type I Interferon Receptor 2 Is Elevated By Interferon Treatment and In Certain Autoimmune Diseases
Taher Fatakdawala¹, Michael Skawinski¹, Jonathan Ferriera², Tara Stauffer¹ and Thomas Lavoie¹, ¹Product Research & Development and Assay Services, PBL Assay Science, Piscataway, NJ, ²Quality Control, PBL Assay Science, Piscataway, NJ
Background/Purpose: The Type I Interferon (IFN) receptor is a heterodimer of chain 1 (IFNAR1) which is required for signaling, and chain 2 (IFNAR2) which binds…
Abstract Number: 934 • 2013 ACR/ARHP Annual Meeting
Interleukin-12B Is Up-Regulated By Decoy Receptor 3 In Specifically Rheumatoid Synovial Fibroblasts
Koji Fukuda¹, Yasushi Miura^1,2, Toshihisa Maeda¹, Shinya Hayashi³ and Masahiro Kurosaka³, ¹Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan, ³Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: Decoy receptor 3 (DcR3) is a secreted decoy tumor necrosis factor receptor and competitively binds and inhibits the TNF family including Fas-ligand (FasL), LIGHT,…
Abstract Number: 2740 • 2013 ACR/ARHP Annual Meeting
High Efficacy Of Toll-Like Receptor 4 Targeting In Murine and Humanized Models Of Rheumatoid Arthritis In Comparison With IL-1 and TNF Inhibitors
Shahla Abdollahi-Roodsaz¹, Marije I. Koenders², Leo A. Joosten³, Fons A. van de Loo⁴ and Wim B. van den Berg¹, ¹Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ³Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ⁴Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands
Background/Purpose: Increased expression of Toll-like Receptor (TLR) 4 and its endogenous agonists in rheumatoid joints suggest involvement in rheumatoid arthritis (RA). The aim of this…
Abstract Number: 1824 • 2013 ACR/ARHP Annual Meeting
ONO-4059 – A Novel Small Molecule Dual Inhibitor Of Bruton’s Tyrosine Kinase (Btk) and Tec Kinase- Suppresses Osteoclastic Bone Resorption and Inflammation
Yuko Ariza¹, Toshio Yoshizawa¹, Yoshiko Ueda¹, Shingo Hotta¹, Tomoko Yasuhiro¹, Masami Narita¹, Yutaka Shichino² and Kazuhito Kawabata¹, ¹Discovery Research Laboratories 3, Ono Pharmaceutical Co., Ltd., Osaka, Japan, ²Discovery Research Laboratories, Ono Pharmaceutical Co., Ltd., Osaka, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by leukocyte infiltration, synoviocyte hyperplasia and osteoclastogenesis, leading to erosion of the joints and cartilage,…
Abstract Number: 941 • 2013 ACR/ARHP Annual Meeting
Mir-34a In Rheumatoid Arthritis: Characterisation Of Elevated Synovial Expression and Association With Treatment Resistance
Clare E Tange¹, Stefano Alivernini², Derek S. Gilchrist³, Lynn Crawford³, Ashleigh-Ann Rainey¹, Derek Baxter³, Iain B. Mcinnes⁴ and Mariola Kurowska-Stolarska⁵, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, ³Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁴Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁵Institute of Infection,Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Cells of the monocyte/macrophage lineage are critical to RA pathogenesis: unravelling mechanisms underlying macrophage inflammatory gene expression should elucidate novel disease-associated pathways and thereby…
Abstract Number: 2657 • 2013 ACR/ARHP Annual Meeting
Interactions Between Cigarette Smoking, Body Mass Index and Inflammatory Cytokine Levels In Determining The Risk Of Developing Rheumatoid Arthritis
Elizabeth V. Arkema¹, Susan Malspeis², Bing Lu³, Linda T. Hiraki⁴, Elizabeth W. Karlson² and Karen H. Costenbader², ¹Epidemiology, Harvard School of Public Health, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA
Background/Purpose: Smoking and high body mass index (BMI) are risk factors for RA. Both are associated with increased systemic inflammation, with elevated C-reactive protein, interleukin…
Abstract Number: 1763 • 2013 ACR/ARHP Annual Meeting
IL4-10 Synerkine: A Novel Immunoregulatory Drug To Prevent Immunopathology In Rheumatic Diseases
Sarita Hartgring¹, Cristine Steen-louws², C.E. Hack³, Martin De Smet⁴, Floris Lafeber⁵ and J.A.G. van Roon⁶, ¹Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology & Clinical Immunology/Lab Translational Immunology, UMC Utrecht, Utrecht, Netherlands, ³Immunology, UMC Utrecht, Utrecht, Netherlands, ⁴Lab Translational Immunology, UMC Utrecht, Utrecht, Netherlands, ⁵Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands, ⁶Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: A considerable percentage of patients shows a limited response to biologics targeting one specific inflammatory mediator, largely because of redundancy of these mediators. An…
Abstract Number: 944 • 2013 ACR/ARHP Annual Meeting
Mir-125a: A Novel Regulator Of IL-6 and TLR Driven Pathways In RA Pathogenesis
Ashleigh-Ann Rainey¹, Derek S. Gilchrist², Clare E Tange¹, Marina Frleta³, Lynn Crawford², Derek Baxter², Iain B. Mcinnes⁴ and Mariola Kurowska-Stolarska⁵, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ³Institute of infection, immunity and inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴University of Glasgow, Glasgow, United Kingdom, ⁵Institute of Infection,Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Molecular mechanisms driving disease initiation and chronicity in RA are incompletely understood. There is increasing interest in the role played therein by microRNAs –…
Abstract Number: 2573 • 2013 ACR/ARHP Annual Meeting
The Role Of STAT-3 In The Development Of Pulmonary and Dermal Fibrosis
Mesias Pedroza¹, Sarah To¹, Anuh T. George¹, David J. Tweardy² and Sandeep K. Agarwal¹, ¹Medicine, Section of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ²Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, TX
Background/Purpose: Fibrosis is the accumulation of excessive extra-cellular matrix in tissues, leading to tissue damage. In systemic sclerosis, the trigger is postulated to be an…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].